



# INTRODUCING **DROP-FREE CATARACT TREATMENT**

**DROP** ... the inconvenience  
of daily drops

**DROP** ... the worry of using  
daily drops incorrectly

**DROP** ... the hassle of relying on  
friends and family for help

**DROP** ... the pressure of getting  
every dose right

**DROP** ... the potential risk of  
poorer outcomes from  
daily drops



## Optegra are pleased to offer patients drop-free cataract surgery nationwide

We place excellent outcomes and a focus to continuously improve patient experience at the very centre of what we do, and this treatment solution reflects that commitment.

Thanks to recent advances, we're now able to provide the same protective benefits that post-operative eye drops traditionally offered, without routine cataract patients following a course of drops after surgery.

An audit of our first 1,000 drop-free patients in October 2025 showed excellent results with no increased risk of pressure spikes. We compared outcomes with 1,000 patients using the traditional 3–4 weeks of post-surgery drops.

Key findings:

- **Equivalent anti-inflammatory protection** to traditional drops, reflecting results from a large US study of 68,000+ patients.\*
- **Very low IOP spike rate:** just 0.3% in drop-free patients, compared with the expected 3.2% in a standard population.\*\*
- **No difference** in cystoid macular oedema rates between groups.

These results show that the drop-free cataract pathway offers **equivalent safety and efficacy** to traditional postoperative care.



**OPT FOR BETTER**  
Scan to learn more  
about Optegra's  
drop-free treatment

\* Shorstein et al.  
*Triamcinolone Acetonide Subconjunctival Injection as Stand-alone Inflammation Prophylaxis after Phacoemulsification Cataract Surgery.*  
*Ophthalmology*, Volume 131: Number 10. October 2024.

\*\* Lidder AK, et al.  
*Intraocular Pressure Spike Following Stand-Alone Phacoemulsification in the IRIS Registry (Intelligent Research in Sight).*  
*Ophthalmology*, Volume 131: 780-789. October 2024